Combination medical treatment for primary open angle glaucoma and ocular hypertension: A network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 11, 2014, Pages

  Michelessi, Manuele ^a,b   Lindsley, Kristina ^b   Yu, Tsung ^b   Li, Tianjing ^b  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN PLUS PILOCARPINE; BETAXOLOL; BETAXOLOL PLUS PILOCARPINE; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE PLUS BRINZOLAMIDE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; BRINZOLAMIDE PLUS TIMOLOL; CARTEOLOL; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; PILOCARPINE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

BEST CORRECTED VISUAL ACUITY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; MONOTHERAPY; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; SYSTEMATIC REVIEW;

EID: 85010057875     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011366     Document Type: Review

References (46)

1. American Academy of Ophthalmology (AAO). Primary angle closure glaucoma. Preferred Practice Patterns Guidelines. San Francisco, CA: American Academy of Opthalmology 2010.
2. Baratz KH, Nau CB, Winter EJ, McLaren JW, Hodge DO, Herman DC, et al.Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea 2006;25(9):1046-52.
3. Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001;108(10):1779-88.
4. Bron AM, Emmerich KH. Latanoprost versus combined timolol and dorzolamide. Survey of Ophthalmology 2002;47 Suppl 1:S148-54.
5. Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD004399.pub3].
6. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8(10):e76654.
7. Chauhan BC, Mikelberg FS, Artes PH, Balazsi AG, LeBlanc RP, Lesk MR, et al.Canadian glaucoma study group. Archives of Ophthalmology 2010;128(10):1249-55.
8. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005;112(9):1487-93.
9. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Medical Decision Making 2013;33:641-56.
10. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. Journal of Glaucoma 2009;18(3):238-43.
11. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Annals of Internal Medicine 1990;112(2):120-5.
12. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Current Opinion in Ophthalmology 2004;15(2):132-5.
13. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al.The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Archives of Ophthalmology 2002;120(6):714-20.
14. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
15. Hurvitz LM, Kaufman PL, Robin AL, Weinreb RN, Crawford K, Shaw B. New developments in the drug treatment of glaucoma. Drugs 1991;41(4):514-32.
16. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Statistics in Medicine 2014;33(21):3639-57.
17. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al.The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology 2002;120(6):701-13.
18. King A, Azuara-Blanco A, Tuulonen A. Glaucoma. BMJ 2013;346:f3518.
19. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Archives of Ophthalmology 2003;121(1):48-56.
20. Leske MC, Wu SY, Honkanen R, Nemesure B, Schachat A, Hyman L, et al.Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology 2007;114(6):1058-64.
21. Li T, Puhan M, Vedula S, Singh S, Dickersin K for the Ad Hoc Network Meta-analysis Methods Meeting Working Group. Network meta-analysis - highly attractive and more methodological research is needed. BMC Medicine 2011;9(1):79.
22. Marcus MW, de Vries MM, Junoy Montolio FG, Jansonius NM. Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. Ophthalmology 2011;118(10):1989-94.
23. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al.A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.
24. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology 2006;90(3):262-7.
25. Quigley HA. Glaucoma. Lancet 2011;377(9774):1367-77.
26. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
27. Rolim de Moura C, Paranhos A Jr, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003919.pub2].
28. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71.
29. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97.
30. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
32. Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma?. Current Opinion in Ophthalmology 2008;19(2):85-8.
33. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient reported behavior and problems in using glaucoma medications. Ophthalmology 2006;113(3):431-6.
34. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, et al.Racial differences in the cause-specific prevalence of blindness in east Baltimore. New England Journal of Medicine 1991;325(20):1412-7.
35. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, et al.Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. The Baltimore Eye Survey. Archives of Ophthalmology 1991;109(8):1092.
36. Sommer A. Ocular hypertension and normal-tension glaucoma: time for banishment and burial. Archives of Ophthalmology 2011;129(6):785-7.
37. College Station, TX: StataCorp LP. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP, 2013.
38. Varma R, Ying-Lai M, Francis BA, Nguyen BB, Deneen J, Wilson MR, et al.Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111(8):1439-48.
39. Varma R, Wang D, Wu C, Francis BA, Nguyen BB, Chopra V, et al.Four-year incidence of open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. American Journal of Ophthalmology 2012;154(2):315-25.
40. Vass C, Hirn C, Sycha T, Findl O, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003167.pub3].
41. Waterman H, Evans JR, Gray TA, Henson D, Harper R. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD006132.pub3].
42. Webers CA, van der Valk R, Schouten JS, Zeegers MP, Prins MH, Hendrikse F. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology 2007;114(1):40-6.
43. Webers CA, Beckers HJ, Nujits RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 2008;25(9):729-59.
44. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363(9422):1711-20.
45. White IR. Multivariate random-effects meta-regression: updates to mvmeta. The STATA Journal 2011;11(2):255-70.
46. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 2012;3(2):111-25.